Rheumnow Podcast

Richard Conway, a vasculitis specialist, discusses pivotal findings from ACR 2024. Peter Nash delves into the role of JAK inhibitors, while Janet Pope reviews treatment strategies for polymyalgia rheumatica and giant cell arteritis. Eric Dian analyzes intriguing oral abstracts on rheumatoid arthritis, and David Liu emphasizes cardiovascular risks associated with treatments. They explore the safety of JAKs, advances in managing RA during COVID-19, and the efficacy of new therapies for PMR and GCA, showcasing innovative strategies for improving patient outcomes.

Andrea Fava is an expert in lupus nephritis diagnostics, while Chris Winkup is a consultant rheumatologist focused on CAR-T therapy. They dive into the challenges of diagnosing lupus nephritis with new non-invasive biomarkers. The discussion highlights the impact of positive ANA patterns on liver disease, and the advancements in CAR-T therapy for targeting harmful B-cells. They also touch upon vaccination responses and the complexities surrounding neuropsychiatric lupus, emphasizing the need for enhanced patient-clinician communication.

Adela Castro presents CLASSIC study results, exploring the ASAS criteria for axSpA. Anthony Chan discusses the BASTI score and defines difficult-to-manage axSpA. Marina Magre highlights key abstracts from the ACR meeting. Dr. Sheila Reyes explains how machine learning predicts flares and the impact of gender on axSpA. Professor Walter Maximowicz shares the 3-4-5 rule for interpreting positive MRI findings, enhancing understanding of spondyloarthritis diagnostics. Together, they showcase significant advancements in research and treatment strategies.

Catherine Bakewell, a seasoned rheumatologist and ultrasound expert, Philip Meese, a dedicated researcher on bimekizumab, and Artie Kavanaugh, an insightful rheumatologist reporting on ACR updates, dive into cutting-edge topics. They discuss the promising results of bimekizumab in alleviating pain and fatigue in psoriatic arthritis. Insights into the implications of weight loss drugs on treatment outcomes are explored, alongside crucial findings on sex differences affecting disease impact, driving home the need for tailored strategies in patient care.

Join Dr. David Liew, a renowned rheumatologist, as he dives into the role of JAK inhibitors in treating polymyalgia rheumatica. He discusses the recent breakthroughs that are reshaping treatment strategies and making these therapies more accessible. The conversation also turns to the cardiovascular risks associated with JAK inhibitors, compared to traditional steroid use. Liew's insights highlight the importance of evaluating both benefits and risks in personalized rheumatology care.

Dr. Guillermo Valenzuela, a leading expert in rheumatology, shares groundbreaking insights on apremilast's efficacy for psoriatic arthritis from the Mosaic Trial. He also discusses an innovative approach to rheumatoid arthritis treatment using an implantable vagus nerve stimulator, showcasing its potential for patients who haven’t responded to standard therapies. The conversation highlights advancements in managing these conditions and the promising implications for patient care.

Joining the discussion are David Liu, a rheumatologist from Melbourne, and Akhil Sood, a fellow at Stanford with expertise in lupus treatment. They dive into groundbreaking studies from the ACR Annual Meeting, spotlighting promising results for Dapirulizumab in lupus care. The conversation shifts to new therapies and the clinical implications for lupus and advancements in AI for diagnosing inflammatory conditions. They also address the risks of steroid use in rheumatic diseases and the emerging management challenges faced by patients.

ACR 24: What I learned in Sjogren's, Takayasu's and CAR-T:Dr. Janet Pope Anti IL-17 on Entheseal Biopsy in PsA:Dr. Eric Dein  axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure:Dr. Brian Jaros Can We Make Clinical Trials Better?:Dr. Janet Pope Cumulative Steroid Use and Cardiovascular Events:Dr. Mrinalini Dey  IL 6 Inhibitors, Frailty and Polymyalgia Rheumatica:Drs. Trish Harkins and Sebastian Sattui IVIG Treatment in Immune-mediated Necrotizing Myopathy:Drs. Caoilfhionn Connolly interviews Dr. Asim Mohamed  Machine Learning for Predicting Flares in axSpA:Dr. Sheila Reyes So really, are JAKs Safe?:Dr. Janet Pope Tackling the Workforce Crisis: A shared dilemma:Drs. Mrinalini Dey,  Louise Pollard and Bharat Kumar The 2024 ACR Guidelines for Lupus Nephritis:Dr. Sheila Reyes  The Real Value of JAKi is Beyond RA:Dr. David Liew  Vaccine Responses:The DMARD Counts:Dr. David Liew

Joining the discussion are Bella Mehta, a New York rheumatologist specializing in autoimmune diseases, Brian Jaros from Chicago, an expert in giant cell arteritis, and Quilin Conley from Galway, focusing on anti-obesity medications. They delve into new lupus nephritis recommendations and explore the interplay between psoriatic arthritis and immunotherapy mortality risks. Additionally, advancements in predicting vision loss in giant cell arteritis are discussed, alongside the potential of GLP-1 medications to benefit rheumatoid arthritis patients, despite challenges like side effects.

Best Things I Saw Today in PsA:Dr. Catherine Bakewell  Do TNFis and JAKis Prevent Cancer!?:Dr. Richard Conway Efficacy and Safety of Nipocalimab for Sjogren's Syndrome:Dr. Mike Putman Evaluating ANA Patterns and Titers with AI:Dr. Bella Mehta Improvements in Pain and Fatigue in Bimekizumab:Dr. Philip Mease  Long Term Follow up from APIPPRA:Dr. Antoni Chan talks with Dr. Andrew Cope Race Neutral PFTs in Scleroderma Improves Equity:Dr. Caoilfhionn Connolly talks with Dr. Kamini Kuchinad  Summary of JAKi Studies:Dr. Peter Nash The Psoriatic March: PsA before PsO:DR. Antoni Chan Use of AI in Hand Ultrasound Scoring:Dr. Bella Mehta  What is MCTD? The Great Debate:Drs. Caoilfhionn Connolly & Lisa Christopher-Stine What's The State of Biosimilars?:Drs. Eric Dein and Jonathan Kay Pred Softly: Steroids:Dr. Jiha Lee talks with Dr. Beth Wallace